Loading...

Michael DeGregorio

TitleProf
InstitutionUniversity of California Davis
Address
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Kao CJ, Wurz GT, Lin YC, Vang DP, Phong B, DeGregorio M. Repurposing ospemifene for potentiating an antigen-specific immune response. Menopause. 2017 Apr; 24(4):437-451. PMID: 27922937.
      View in: PubMed
    2. Wurz GT, Kao CJ, DeGregorio M. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol. 2016 Jan; 8(1):4-31. PMID: 26753003; PMCID: PMC4699263.
    3. Kao CJ, Wurz GT, Lin YC, Vang DP, Griffey SM, Wolf M, DeGregorio M. Assessing the Effects of Concurrent versus Sequential Cisplatin/Radiotherapy on Immune Status in Lung Tumor-Bearing C57BL/6 Mice. Cancer Immunol Res. 2015 Jul; 3(7):741-50. PMID: 25672395.
      View in: PubMed
    4. Wurz GT, Kao CJ, DeGregorio M. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause. Clin Interv Aging. 2014; 9:1939-50. PMID: 25419123; PMCID: PMC4235480.
    5. DeGregorio M, Zerbe RL, Wurz GT. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy. Steroids. 2014 Nov; 90:82-93. PMID: 25087944.
      View in: PubMed
    6. DeGregorio M, Soe L, Wolf M. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small cell lung cancer (START): a randomized, double-blind, phase III trial. J Thorac Dis. 2014 Jun; 6(6):571-3. PMID: 24976972; PMCID: PMC4073360.
    7. Kao CJ, Wurz GT, Monjazeb AM, Vang DP, Cadman TB, Griffey SM, Wolf M, DeGregorio M. Antitumor effects of cisplatin combined with tecemotide immunotherapy in a human MUC1 transgenic lung cancer mouse model. Cancer Immunol Res. 2014 Jun; 2(6):581-9. PMID: 24894093.
      View in: PubMed
    8. Wurz GT, DeGregorio M. Response to: "Deceptive argumentation against diagnostic microdosing of anticancer drugs" by Dirk Theile and Gerd Mikus (Letter dated February 13, 2014). Int J Cancer. 2014 Oct 01; 135(7):1751-2. PMID: 24615713.
      View in: PubMed
    9. Wurz GT, DeGregorio M. Activating adaptive cellular mechanisms of resistance following sublethal cytotoxic chemotherapy: implications for diagnostic microdosing. Int J Cancer. 2015 Apr 01; 136(7):1485-93. PMID: 24510760.
      View in: PubMed
    10. Wurz GT, Kao CJ, Wolf M, DeGregorio M. Tecemotide: an antigen-specific cancer immunotherapy. Hum Vaccin Immunother. 2014; 10(11):3383-93. PMID: 25483673; PMCID: PMC4514140.
    11. Vang DP, Wurz GT, Griffey SM, Kao CJ, Gutierrez AM, Hanson GK, Wolf M, DeGregorio M. Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice: a model for immunotherapy development. J Vis Exp. 2013 Oct 30; (80):e50868. PMID: 24300078; PMCID: PMC3965342.
    12. Soe LH, Wurz GT, Kao CJ, Degregorio MW. Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast. Int J Womens Health. 2013 Sep 25; 5:605-11. PMID: 24109197; PMCID: PMC3792833.
    13. Kao CJ, Wurz GT, Schröder A, Wolf M, Degregorio MW. Clarifying the pharmacodynamics of tecemotide (L-BLP25)-based combination therapy. Oncoimmunology. 2013 Oct 01; 2(10):e26285. PMID: 24498545.
      View in: PubMed
    14. Wurz GT, Gutierrez AM, Greenberg BE, Vang DP, Griffey SM, Kao CJ, Wolf M, DeGregorio M. Antitumor effects of L-BLP25 antigen-specific tumor immunotherapy in a novel human MUC1 transgenic lung cancer mouse model. J Transl Med. 2013 Mar 13; 11:64. PMID: 23496860; PMCID: PMC3605365.
    15. Wurz GT, Soe LH, DeGregorio M. Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas. 2013 Mar; 74(3):220-5. PMID: 23332519.
      View in: PubMed
    16. Degregorio M, Degregorio M, Wurz GT, Wurz GT, Gutierrez A, Gutierrez A, Wolf M. L-BLP25 vaccine plus letrozole for breast cancer: Is translation possible? Oncoimmunology. 2012 Nov 01; 1(8):1422-1424. PMID: 23243615.
      View in: PubMed
    17. Mehta NR, Wurz GT, Burich RA, Greenberg BE, Griffey S, Gutierrez A, Bell KE, McCall JL, Wolf M, DeGregorio M. L-BLP25 vaccine plus letrozole induces a TH1 immune response and has additive antitumor activity in MUC1-expressing mammary tumors in mice. Clin Cancer Res. 2012 May 15; 18(10):2861-71. PMID: 22434666.
      View in: PubMed
    18. Burich RA, Mehta NR, Wurz GT, McCall JL, Greenberg BE, Bell KE, Griffey SM, DeGregorio M. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause. 2012 Jan; 19(1):96-103. PMID: 21926925; PMCID: PMC3246110.
    19. McCall JL, DeGregorio M. Pharmacologic evaluation of ospemifene. Expert Opin Drug Metab Toxicol. 2010 Jun; 6(6):773-9. PMID: 20429673.
      View in: PubMed
    20. Wurz GT, Hellmann-Blumberg U, DeGregorio M. Pharmacologic effects of ospemifene in rhesus macaques: a pilot study. Basic Clin Pharmacol Toxicol. 2008 Jun; 102(6):552-8. PMID: 18346046.
      View in: PubMed
    21. Wurz GT, Marchisano-Karpman C, DeGregorio M. Ineffectiveness of American ginseng in the prevention of dimethylbenzanthracene-induced mammary tumors in mice. Oncol Res. 2006; 16(6):251-60. PMID: 17476970.
      View in: PubMed
    22. Komi J, Lankinen KS, DeGregorio M, Heikkinen J, Saarikoski S, Tuppurainen M, Halonen K, Lammintausta R, Väänänen K, Ylikorkala O, Erkkola R. Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. J Bone Miner Metab. 2006; 24(4):314-8. PMID: 16816926.
      View in: PubMed
    23. Namba R, Young LJ, Maglione JE, McGoldrick ET, Liu S, Wurz GT, DeGregorio M, Borowsky AD, MacLeod CL, Cardiff RD, Gregg JP. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Res. 2005; 7(6):R881-9. PMID: 16280035; PMCID: PMC1410776.
    24. Wurz GT, Read KC, Marchisano-Karpman C, Gregg JP, Beckett LA, Yu Q, Degregorio MW. Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol. 2005 Nov; 97(3):230-40. PMID: 16153821.
      View in: PubMed
    25. Komi J, Lankinen KS, Härkönen P, DeGregorio M, Voipio S, Kivinen S, Tuimala R, Vihtamäki T, Vihko K, Ylikorkala O, Erkkola R. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause. 2005 Mar; 12(2):202-9. PMID: 15772568.
      View in: PubMed
    26. Paterniti DA, Melnikow J, Nuovo J, Henderson S, DeGregorio M, Kuppermann M, Nease R. "I'm going to die of something anyway": women's perceptions of tamoxifen for breast cancer risk reduction. Ethn Dis. 2005; 15(3):365-72. PMID: 16108294.
      View in: PubMed
    27. Morello KC, Wurz GT, DeGregorio M. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet. 2003; 42(4):361-72. PMID: 12648026.
      View in: PubMed
    28. Perez EA, Gandara DR, Edelman MJ, O'Donnell R, Lauder IJ, DeGregorio M. Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Cancer Invest. 2003; 21(1):1-6. PMID: 12643003.
      View in: PubMed
    29. Morello KC, Wurz GT, DeGregorio M. SERMs: current status and future trends. Crit Rev Oncol Hematol. 2002 Jul; 43(1):63-76. PMID: 12098608.
      View in: PubMed